jnj-20210422
0000200406false00002004062021-04-222021-04-220000200406us-gaap:CommonStockMember2021-04-222021-04-220000200406jnj:A0.250NotesDue2022Member2021-04-222021-04-220000200406jnj:A0.650NotesDue2024Member2021-04-222021-04-220000200406jnj:A5.50NotesDue2024Member2021-04-222021-04-220000200406jnj:A1.150NotesDue2028Member2021-04-222021-04-220000200406jnj:A1.650NotesDue2035Member2021-04-222021-04-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
April 22, 2021
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey1-321522-1024240
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $1.00JNJNew York Stock Exchange
0.250% Notes Due January 2022JNJ22New York Stock Exchange
0.650% Notes Due May 2024JNJ24CNew York Stock Exchange
5.50% Notes Due November 2024JNJ24BPNew York Stock Exchange
1.150% Notes Due November 2028JNJ28New York Stock Exchange
1.650% Notes Due May 2035JNJ35New York Stock Exchange
 
  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





Item 5.07 Submission of Matters to a Vote of Security Holders.

(a)    The 2021 Annual Meeting of Shareholders was held on April 22, 2021.

(b)    At the 2021 Annual Meeting of Shareholders, the shareholders:

elected all 14 Director nominees named in the 2021 Proxy Statement to the Company's Board of Directors;

approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the “Compensation Discussion and Analysis” section of the 2021 proxy statement and the compensation of the Company's executive officers named in the 2021 Proxy Statement, as disclosed therein;

ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year 2021;

did not approve the shareholder proposal for a report on government financial support and access to COVID-19 vaccines and therapeutics;

did not approve the shareholder proposal for an independent board chair;

did not approve the shareholder proposal for a civil rights audit; and

did not approve the shareholder proposal for executive compensation bonus deferral.

The following are the final voting results for each of the seven items voted on at the meeting.

1.    Election of Directors:
Shares ForShares AgainstShares AbstainNon-Votes
M. C. Beckerle1,810,423,629 16,477,577 4,324,787 361,631,706 
D. S. Davis1,760,086,673 65,980,033 5,159,287 361,631,706 
I. E. L. Davis1,788,731,967 37,515,980 4,978,046 361,631,706 
J. A. Doudna1,814,385,723 12,552,555 4,287,715 361,631,706 
A. Gorsky1,699,594,759 119,253,059 12,378,175 361,631,706 
M. A. Hewson1,777,336,871 49,480,838 4,408,284 361,631,706 
H. Joly1,775,886,493 50,205,313 5,134,187 361,631,706 
M. B. McClellan1,808,590,798 17,138,760 5,496,435 361,631,706 
A. M. Mulcahy1,614,611,649 195,380,452 21,233,892 361,631,706 
C. Prince1,649,989,314 176,521,719 4,714,960 361,631,706 
A. E. Washington1,773,129,639 53,253,564 4,842,790 361,631,706 
M. A. Weinberger1,809,184,712 16,475,730 5,565,551 361,631,706 
N. Y. West1,817,859,141 8,942,629 4,424,223 361,631,706 
R. A. Williams1,749,060,576 77,138,736 5,026,681 361,631,706 


2.    Advisory Vote to Approve Named Executive Officer Compensation:
For986,844,148 
Against753,486,152 
Abstain90,895,693 
Non-Votes361,631,706 





3.    Ratification of Appointment of PricewaterhouseCoopers LLC as the Independent Registered Public Accounting Firm for 2021:
For2,080,036,325 
Against108,538,970 
Abstain4,282,404 
Non-VotesN/A


4.    Shareholder Proposal - Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics:

For573,465,487 
Against1,231,071,897 
Abstain26,688,609 
Non-Votes361,631,706 


5.    Shareholder Proposal - Independent Board Chair:
For789,938,907 
Against1,032,409,877 
Abstain8,877,209 
Non-Votes361,631,706 


6.    Shareholder Proposal - Civil Rights Audit:
For611,417,042 
Against1,192,232,580 
Abstain27,576,371 
Non-Votes361,631,706 

7.    Shareholder Proposal - Executive Compensation Bonus Deferral
For410,065,480 
Against1,406,949,986 
Abstain14,210,527 
Non-Votes361,631,706 




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 Johnson & Johnson 
   (Registrant)
 
 
 
 
Date: April 26, 2021By:/s/ Matthew Orlando 
  Matthew Orlando
Secretary